Therapeutic Drug Monitoring Model¶
Clinical protocol — instantiates Dose–Exposure–Response Trajectory Modeling
A clinical measure-and-adjust protocol that compares observed drug levels against a target window and corrects the dose while a safety override guards the boundary.
Therapeutic Drug Monitoring Model is the governed control loop of the archetype — the standing clinical protocol that closes the loop between measuring a drug level and changing the dose. Its defining move is to be a procedure with authority, not a model: it specifies which level to measure, when to draw it, what target window it must fall in, how to adjust the dose when it is out of range, and — critically — an independent safety override that halts or reduces dosing when a boundary is breached, regardless of what any optimizing model recommends. It is the mechanism that turns forecasting into standing clinical practice. It typically consumes a forecasting model to interpret each level, but its own contribution is the disciplined observe-compare-adjust-guard cycle wrapped in governance, so that dosing stays inside the safe-and-effective band across an entire course of therapy.
Example¶
A patient receives a kidney transplant and is started on tacrolimus, an immunosuppressant that must stay in a narrow band: too low risks organ rejection, too high causes kidney toxicity from the very drug meant to protect the graft. The Therapeutic Drug Monitoring protocol governs the whole course. It specifies a trough measurement — a blood level drawn just before the next dose — on a defined schedule: daily at first, then weekly as the patient stabilizes. Each trough is compared against the target window for this post-transplant stage. When a level lands below the window, the protocol's adjustment rule raises the dose by a specified increment; when it lands above, the dose is cut. A separate safety override sits on top: if a level crosses a hard toxicity threshold, or kidney-function markers deteriorate, dosing is held and reviewed immediately, without waiting for the routine adjustment logic.[n1] The protocol does not forecast the trajectory itself — it borrows a model for that — but it is what ensures the drug is measured, compared, and corrected reliably, month after month, by whoever is on shift.
How it works¶
- Draw the right observation. Specify the sample (e.g., trough), its timing relative to dosing, and how to handle a mistimed or missing draw.
- Compare against the window. Place the measured level inside or outside the stage-specific target range.
- Apply the adjustment rule. Move the dose by the protocol's specified increment (or via a consumed model's recommendation) to bring the next level into range.
- Enforce the override independently. A safety rule, separate from the optimizing logic, halts or reduces dosing at hard boundaries and triggers review — so a model error cannot dose a patient into harm.
Tuning parameters¶
- Sampling cadence — how often levels are drawn. Frequent sampling catches drift early but burdens patient and lab; it is loosened as the patient stabilizes.
- Target window width — how tight the acceptable range is. Narrower windows chase precision but trigger more adjustments and more boundary alarms.
- Adjustment step size — how aggressively the dose is corrected per out-of-range level; large steps converge fast but risk over-correcting a lagged system.
- Override thresholds — the hard limits that trip the safety rule; set conservatively, they favor holding over optimizing near danger.
- Interpretation source — a fixed nomogram versus a consumed forecasting model; richer interpretation individualizes better but adds dependence and opacity.
When it helps, and when it misleads¶
Its strength is durable, staff-proof control: it keeps a narrow-window drug in range across a long course, through shift changes and varying expertise, because the measure-compare-adjust-guard steps are written down and the safety override is independent of any model's optimism.
Its central failure mode is monitoring-channel drift and single-number tyranny: a mistimed trough, an assay change, or a lab delay quietly corrupts the input, and the protocol dutifully adjusts to a wrong number; worse, a single trough is a thin proxy for the true exposure it is standing in for, so chasing it can miss the actual trajectory. The classic misuse is titrating hard to a lone level drawn at the wrong time. The guarding discipline is to protect the observation channel (timing, assay consistency, missingness handling) as carefully as the dose logic, and to keep the safety override strictly independent so the model that recommends the dose never gets to optimize away the boundary that constrains it.
How it implements the components¶
Therapeutic Drug Monitoring Model fills the governed closed-loop face of the archetype:
observation_update_channel— the protocol is the disciplined measurement channel: which level, drawn when, with rules for mistimed or missing samples.dosing_or_control_decision_rule— the out-of-range adjustment logic that changes the dose to bring the next level into the window.operating_window_constraint— the stage-specific target range every measured level is judged against.safety_override_rule— an independent hard-boundary rule that halts or reduces dosing and forces review, separate from the optimizing logic.
It does not itself forecast the trajectory: the generative exposure_state_model, exposure_response_function, and probabilistic prediction_uncertainty_band are supplied by Bayesian Dose Forecasting, which this protocol consumes to interpret each level rather than authoring the model.
Related¶
- Instantiates: Dose–Exposure–Response Trajectory Modeling — supplies the closed-loop, governed control practice that keeps a live system inside its window.
- Consumes: Bayesian Dose Forecasting to interpret each measured level and recommend the next dose.
- Sibling mechanisms: Bayesian Dose Forecasting · Compartmental PK/PD Model · Effect-Compartment Lag Model · Exposure–Response Simulation · Physiologically Based Exposure–Response Model · Policy Exposure–Response Sandbox · Population PK/PD Covariate Model · Training Load Response Forecast
Editorial Notes¶
Form Classification¶
Form family: Control, Automation & Runtime
Rationale: Therapeutic Drug Monitoring Model operates as a live operational control that automatically routes, enforces, adapts, or responds during execution because it a clinical measure-and-adjust protocol that compares observed drug levels against a target window and corrects the dose while a safety override guards the boundary.
Independent corroboration: The frozen evidence defines Therapeutic Drug Monitoring Model as 'A clinical measure-and-adjust protocol that compares observed drug levels against a target window and corrects the dose while a safety override guards the boundary', so its operative form is Control, Automation & Runtime.
Nearest alternative: Protocol, Workflow & Routine — Therapeutic Drug Monitoring Model includes features of a repeatable ordered procedure or handoff sequence that coordinates action, but its defining operation is a live operational control that automatically routes, enforces, adapts, or responds during execution.
Review outcome: Independent reviewer agreement; medium confidence.
Origin Attribution¶
Primary origin: Medicine & Healthcare
Origin pattern: Cross-disciplinary synthesis
Present-day reach: Universal
Rationale: Therapeutic drug monitoring model derives most directly from medicine's diagnosis, therapeutic monitoring, and patient-safety tradition; its defining operation is to a clinical measure-and-adjust protocol that compares observed drug levels against a target window and corrects the dose while a safety override guards the boundary.
Related originating lineages:
- Psychology — Experimental, clinical, and behavioral psychology supplies a parallel or contributing lineage for the mechanism's defining operation: a clinical measure-and-adjust protocol that compares observed drug levels against a target window and corrects the dose while a safety override guards the boundary.
- Statistics & Experimental Design — Statistics' measurement, sampling, inference, and experimental-design tradition provides a formative adjacent lineage for the same therapeutic drug monitoring model operation.
- Systems Thinking & Cybernetics — Systems thinking, feedback control, and cybernetics supplies a parallel or contributing lineage for the mechanism's defining operation: a clinical measure-and-adjust protocol that compares observed drug levels against a target window and corrects the dose while a safety override guards the boundary.
Review resolution: Both blind reviewers independently select medicine_healthcare as the primary historical origin for the concrete operation—A clinical measure-and-adjust protocol that compares observed drug levels against a target window and corrects the dose while a safety override guards the boundary. The queued differences concern alternate origin disagreement, origin mode disagreement, domain reach disagreement, encyclopedia synthesis disagreement, not the primary lineage. I retain every alternate that either reviewer explains, without a numeric cap, and choose origin_mode=cross_disciplinary_synthesis because the reviewers' combined evidence identifies material construction from multiple disciplines. domain_reach=universal records later portability rather than multiplying historical origins; confidence=high is the conservative shared evidentiary level, and encyclopedia_synthesis=true preserves either reviewer's affirmative synthesis finding.
Encyclopedia synthesis: The exact catalogued form synthesizes established practice rather than reproducing a single standard historical label.
Review outcome: Reconciled after independent review; high confidence.
Notes¶
[n1] A single trough concentration is a convenient but partial proxy for total exposure; the field's move toward area-under-the-curve (AUC)–guided targets for some drugs reflects exactly the risk this protocol must guard against — that one well-placed number can misrepresent the trajectory it stands for. ↩